GNSZ News Alert Genspera Inc (GNSZ) 0.6610 12/26/2014 00:47:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genspera Inc (GNSZ) 0.6610 $GNSZ

H.C. Wainwright & Co. Initiates Coverage of GenSpera with a Buy Rating
ACCESSWIRE - Wed Dec 17, 11:05AM CST
New York, NY / ACCESSWIRE / December 17, 2014 / Market Exclusive announces that H.C. Wainwright & Co has initiated coverage with a Buy rating of GenSpera, Inc. (OTCQB: GNSZ) and a 12-month target price of $2.

Genspera, Inc. Featured in TheStockRadio.com Interview
PR Newswire - Tue Dec 02, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing innovative prodrug therapeutics for the treatment of cancer, releases a recent audio interview with TheStockRadio.com. Craig Dionne, PhD, GenSpera's CEO, discusses the company's background and history including the inception and development of the company's lead compound, mipsagargin, at John Hopkins University and its subsequent development by the company. Dr. Dionne also highlights the benefits of mipsagargin over traditional chemotherapeutics, including its limited side effects and more effective tumor killing properties.

Genspera Announces Melanie Thomas, MD, MS, Will Serve Company as Medical Advisor
PR Newswire - Thu Oct 16, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that Melanie Thomas, MD, MS, a recognized worldwide leader in the field of liver cancer, will join the company as Medical Advisor.

GenSpera Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients
PR Newswire - Thu Oct 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that patient enrollment has been completed in the company's Phase II clinical trial in patients with liver cancer (hepatocellular carcinoma). Formal results of the study are expected to be available during the first quarter of 2015.

GenSpera to Present Lead Drug Candidate Mipsagargin at 2nd Global Life Sciences Conference in Warsaw, Poland
PR Newswire - Tue Sep 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces Craig Dionne, PhD, GenSpera's CEO, will be presenting at the upcoming 2nd Global Life Sciences Conference on October 2, 2014, in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange.

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 91.29 (+1.84), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), LLY: 70.16 (+0.42), ARNA: 3.57 (-0.01), DOW: 46.01 (+0.03), CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01)

Genspera Wins Summary Judgment in Mhaka Litigation
PR Newswire - Thu Sep 18, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States District Court for the District of Maryland has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

GenSpera Receives Patent on Prodrug Targeted for Prostate Cancer
PR Newswire - Tue Sep 09, 7:20AM CDT
GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs."

GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company's presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.

Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
JNJ: 104.59 (+0.31), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), INFI: 16.65 (+0.37), LLY: 70.16 (+0.42)

GenSpera Announces Generic Name "Mipsagargin" for Lead Drug Candidate G-202 per Recommendation by World Health Organization
PR Newswire - Wed Sep 03, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin" (mip sa gar' jin) for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer). Mipsagargin was also recommended by the United States Adopted Names Council (USAN) of the American Medical Association.

GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids
PR Newswire - Thu Aug 28, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids.

GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Thu Aug 14, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

GenSpera Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer
PR Newswire - Wed Jul 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.

Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available
PR Newswire - Tue Jul 22, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and investors.

Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
JNJ: 104.59 (+0.31), SGEN: 31.10 (-0.14), PFE: 31.42 (-0.03), CDXS: 2.45 (-0.03), LLY: 70.16 (+0.42)

GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
PR Newswire - Tue Jul 15, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5th Asia-Pacific Primary Liver Cancer Expert Meeting Saturday, July 12th, in Taipei, Taiwan.

Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
PR Newswire - Mon Jul 14, 8:20AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company.

GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei
PR Newswire - Mon Jul 07, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13th in Taipei, Taiwan.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 23

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 28

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 91

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 13

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 0

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 75

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Eli Lilly's Short Interest Trends and Market Sentiment

Updated Category News Views 217

Eli Lilly's Short Interest Overview The short interest for Eli Lilly has noticeably risen by 14.71% since the last report. Currently, there are about 6.27 million shares that have been sold short, which accounts for roughly 0.78% of all regularly traded shares. At the present trading volume, analysts estimate that it would take around 2.41 days for traders to close out...

Continue Reading
Bluevua Expands Reach with Major Online Retailers

Updated Category News Views 21

An Ecommerce Splash for Water Purification Here we are, diving headfirst into yet another tale of market expansion. Bluevua, a name that's been making waves with its reverse osmosis (RO) systems, just secured a roster spot on some of the biggest online retail giants: Target.com, Lowes.com, and Walmart.com. Sure, not every trader is into the nitty-gritty of water...

Continue Reading
Building Products M&A Trends Indicate a Bright Future Ahead

Updated Category News Views 108

Building Products M&A Trends: A Bright Future Ahead The building products mergers and acquisitions (M&A) sector is on the verge of significant growth as we approach 2026. This promising trajectory is rooted in the optimism surrounding the long-term prospects of the U.S. housing market. An analysis provided by experts in the industry illustrates the resilient nature of...

Continue Reading
Recursion to Share Pivotal REC-4881 Data at DDW 2025 Event

Updated Category News Views 499

Recursion to Share Pivotal REC-4881 Data at DDW 2025 Event Recursion, a pioneering clinical stage TechBio company, is set to unveil groundbreaking preliminary data regarding REC-4881 during the prominent Digestive Disease Week (DDW) event in 2025. This gathering is critical as it showcases advancements in gastrointestinal medicine and research. The data will be...

Continue Reading
Reviving the Legend: Remus Bourbon's Babe Ruth Reserve 2025

Updated Category News Views 258

Reviving a Baseball Legend with Remus Bourbon Remus Bourbon is excited to introduce its latest release, the 2025 Babe Ruth Reserve. This special edition pays homage to Babe Ruth, an icon in the world of baseball known as the Sultan of Swat. With only 8,399 bottles available, this limited production truly captures the spirit of both the game and the whiskey-making...

Continue Reading